Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.015
Sell
RSI(14)
40.589
Neutral
STOCH(KDJ)(9,3,3)
25.579
Buy
ATR(14)
0.072
High Vlolatility
CCI(14)
-86.000
Neutral
Williams %R
77.539
Sell
TRIX(12,20)
-0.663
Sell
StochRSI(14)
71.615
Buy
Search
TELA Bio Inc
TELAAdd to Watchlist
0.707USD
+0.029+4.35%
Market hours （ET）Quotes delayed by 15 min
31.65MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+4.35%
5 Days
-3.51%
1 Month
-3.23%
6 Months
-27.21%
Year to Date
-40.08%
1 Year
-64.29%
Key Figures
0.677Open
0.720High
16.11KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.04%Turnover Ratio
0.677Prev. Close
0.677Low
10.34KTurnover
LossP/E Static
-6.09P/B
0.00%Div Yield TTM
-54.15%ROA
2.20052wk High
2.92Volume Ratio
-37.84MNet Profit
44.77MShares
-0.7926EPS TTM
1.30Beta
-616.62%ROE
0.50152wk Low
6.29%Amplitude
65.69%Gross Margin
31.65MMarket Cap
-1.64Reward/Risk
5.89%Risk Rate
TradingKey Stock Score of TELA Bio Inc
Currency: USD Updated: 2026-07-29Key Insights
TELA Bio Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 71 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.25.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TELA Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
TELA Bio Inc Highlights
StrengthsRisks
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 37.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 80.28M.
Overvalued
The company’s latest PE is -0.85, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.85M shares, decreasing 15.76% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.73.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
2.250
Target Price
+246.15%
Upside Space
TELA Bio Inc News
US-Iran Ceasefire Hits Oil Prices Over 10% as US Stock Futures Surge Pre-Market
Easing tensions in the Middle East triggered a plunge of over 10% in crude oil prices, while the three major U.S. stock index futures and star tech stocks rallied broadly.
TradingKeyWed, Apr 8
Unveiling U.S. Stock “Money Printing Machines” — Insights Into the Business Essence of Star Stocks From Net Profit Margins
Using net profit margin as the core metric, this article provides an in-depth analysis of the business fundamentals of star stocks such as NVIDIA, Tesla, Apple, and Visa. Against the backdrop of a neutral-to-tight monetary environment, it reveals the profitability reality behind the S&P 500’s 13.2% benchmark and accurately identifies U.S. "money-printing machines" possessing significant pricing power.
TradingKeyThu, Apr 2
Earnings Forecast
Analyst Rating
Based on
5
analysts
Buy
Current Rating
2.250
Target Price
+246.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
TELA Bio Inc
TELA
5
Medtronic PLC
MDT
34
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Stryker Corp
SYK
31
Abbott Laboratories
ABT
31
1
2
3
...
22
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.680
Buy
MA10
0.705
Buy
MA20
0.752
Sell
MA50
0.812
Sell
MA100
0.793
Sell
MA200
0.945
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
TELA Bio Inc Info
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Ticker SymbolTELA
CompanyTELA Bio Inc
CEOKoblish (Antony)
Websitehttps://www.telabio.com/
Shareholders
Related Instruments
-0.56%
-2.41%
-2.89%
-0.96%
-1.26%
-1.78%
-1.25%
-2.16%
-2.86%
-1.19%
-2.78%
-1.87%
-1.93%
+0.39%
-1.78%
-2.44%
-0.21%
-1.20%
+4.56%
-1.76%Popular Instruments
51860.400
+302.400 (+0.59%)
28020.000
+906.200 (+3.34%)
7399.100
+96.300 (+1.32%)
14791.000
+105.000 (+0.71%)
63260.000
+2331.000 (+3.83%)
6357.000
+136.500 (+2.19%)
83.450
-0.491 (-0.58%)
330.910
-7.280 (-2.15%)
196.932
+6.922 (+3.64%)
4104.020
+36.880 (+0.91%)
FAQs
What is the current price of TELA Bio Inc (TELA)?
The current price of TELA Bio Inc (TELA) is 0.68.
What is the symbol of TELA Bio Inc?
The ticker symbol of TELA Bio Inc is TELA.
What is the 52-week high of TELA Bio Inc?
The 52-week high of TELA Bio Inc is 2.20.
What is the 52-week low of TELA Bio Inc?
The 52-week low of TELA Bio Inc is 0.50.
What is the market capitalization of TELA Bio Inc?
The market capitalization of TELA Bio Inc is 30.28M.
Is TELA Bio Inc (TELA) currently rated as Buy, Hold, or Sell?
According to analysts, TELA Bio Inc (TELA) has an overall rating of Buy, with a price target of 2.25.
What is the Earnings Per Share (EPS TTM) of TELA Bio Inc (TELA)?
The Earnings Per Share (EPS TTM) of TELA Bio Inc (TELA) is -0.83.